Apollo Endosurgery, Inc. to Report Third Quarter Results on October 30, 2019

AUSTIN, Texas–(BUSINESS WIRE)–Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2019 on Wednesday, October 30, 2019, after the U.S. stock markets close.

Apollo will hold a conference call on Wednesday, October 30, 2019 at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (877) 823-8673 for domestic callers and (647) 689-4156 for international callers. The conference ID number is 6392218. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.apolloendo.com.

A replay of the webcast will be made available on Apollo’s website, www.apolloendo.com, shortly after completion of the call.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 80 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol “APEN”. For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contacts

Apollo Endosurgery, Inc.

Stefanie Cavanaugh, 512-279-5100

investor-relations@apolloendo.com

Darrow Associates Investor Relations

Matt Kreps, 214-597-8200

mkreps@darrowir.com

Staff

Recent Posts

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…

4 hours ago

AARC Celebrates Introduction of the SOAR Act in the House of Representatives

Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…

7 hours ago

She Is Not Skipping a Beat, and Patients Are Noticing

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…

7 hours ago

Innovaccer Launches AI Advisory Board to Drive Advances in Artificial Intelligence

Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…

10 hours ago

Virtual Second Opinions Save Over $8,700 Per Patient, New Analysis Finds

Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…

10 hours ago